MELANOMA BRIDGE 2018
Royal Continental Hotel, Naples, Italy
November 29th - December 1st, 2018
Presidents
Nicola Mozzillo
Honorary President
Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy
Corrado Caracò
Chief of advanced melanoma treatment, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy
Igor Puzanov
Professor of Medicine, Director of Early Phase Clinical Trials Program, Melanoma Section Chief and Co-Leader of Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
Scientific Board
Sanjiv Agarwala
Chief of Medical oncology and Hematology, St. Luke’s University Hospital and Temple University, Bethlehem, Pennsylvania
Paolo A. Ascierto
Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy
Carlo Bifulco
Earle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Portland Medical Center, Portland, Oregon
Lisa H. Butterfield
Professor of Medicine, Surgery, Immunology and Clinical and Translational Science at the University of Pittsburgh and Director of the Immunologic Monitoring and Cellular Products Laboratory (IMCPL) at the UPMC Hillman Cancer Center, Pittsburgh, USA
Corrado Caracò
Chief of advanced melanoma treatment, National Cancer Institute "Fondazione G. Pascale" of Naples, Italy
Reinhard Dummer
Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland
Bernard A. Fox
Chief of the Laboratory of Molecular and Tumor Immunology, Oregon Health and Science University, Providence Cancer Center, Portland Medical Center, Oregon
Jerome Galon
Research Director, National Institute of Health and Medical Research (INSERM), Paris, France
Claus Garbe
University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology Eberhard Karls University Tuebingen, Germany
Giuseppe Masucci
Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden
Michael Postow
Memorial Sloane Kettering Cancer Center, New York, New York
Igor Puzanov
Professor of Medicine, Director of Early Phase Clinical Trials Program, Melanoma Section Chief and Co-Leader of Developmental Therapeutics Program, Roswell Park Comprehensive Cancer Center, Buffalo, New York, USA
Magdalena Thurin
Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland
For information please contact info@melanomabridge.org
